BioPharma Resources

Drug Trial Radar · NCT06430801

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Moderately to Severely Active Crohn's Disease

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,200

Planned (sponsor's estimate)

Start

Jun 5, 2024

Primary completion

Oct 30, 2028

Study completion Nov 12, 2029

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
May 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 52 (US/FDA and EU/EMA), and that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 12 (US/FDA and EU/EMA). Study 2's primary hypothesis is that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 12 (US/FDA and EU/EMA).

Conditions

  • Crohn's Disease

Interventions

  • IV TulisokibartDrug

    Humanized monoclonal antibody that binds human tumor necrosis factor-like cytokine 1A (TL1A), administered intravenously

  • SC TulisokibartDrug

    Humanized monoclonal antibody that binds human TL1A, administered subcutaneously

  • IV PlaceboOther

    Placebo matching IV tulisokibart

  • SC PlaceboOther

    Placebo matching SC tulisokibart

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Study 1 [US/FDA Only]: Percentage of Participants Achieving Clinical Remission per Crohn's Disease Activity Index (CDAI) Score at Week 52Time frame: Week 52
  2. Study 1 [EU/EMA Only]: Percentage of Participants Achieving Clinical Remission per Stool Frequency and Abdominal Pain Score at Week 52Time frame: Week 52
  3. Study 1: Percentage of Participants Achieving Endoscopic Response at Week 52Time frame: Week 52
  4. Study 1 [US/FDA Only]: Percentage of Participants Achieving Clinical Remission per CDAI Score at Week 12Time frame: Week 12
  5. Study 1 [EU/EMA Only]: Percentage of Participants Achieving Clinical Remission per Stool Frequency and Abdominal Pain Score at Week 12Time frame: Week 12
  6. Study 1: Percentage of Participants Achieving Endoscopic Response at Week 12Time frame: Week 12
  7. Study 2 [US/FDA Only]: Percentage of Participants Achieving Clinical Remission per CDAI Score at Week 12Time frame: Week 12
  8. Study 2 [EU/EMA Only]: Percentage of Participants Achieving Clinical Remission per Stool Frequency and Abdominal Pain Score at Week 12Time frame: Week 12
  9. Study 2: Percentage of Participants Achieving Endoscopic Response at Week 12Time frame: Week 12

Locations

499 sites in 47 countries. Site status is shown where the registry gives one.

  • Digestive Health Specialists ( Site 5064)

    Dothan, Alabama · Completed

  • Arizona Arthritis & Rheumatology Research, PC ( Site 5094)

    Phoenix, Arizona · Completed

  • GI Alliance - Sun City ( Site 5118)

    Sun City, Arizona · Recruiting

  • University of Arizona Clinical and Translational Sciences Research Center ( Site 5111)

    Tucson, Arizona · Recruiting

  • University of Arkansas for Medical Sciences ( Site 5147)

    Little Rock, Arkansas · Recruiting

  • Clinnova Research ( Site 5110)

    Anaheim, California · Recruiting

  • Southern California Research Center ( Site 5044)

    Coronado, California · Recruiting

  • Om Research LLC ( Site 5038)

    Lancaster, California · Recruiting

  • Cedars Sinai Medical Center ( Site 5080)

    Los Angeles, California · Recruiting

  • UCLA Clinical & Translational Research Center (CTRC) ( Site 5116)

    Los Angeles, California · Recruiting

  • University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 5128)

    Orange, California · Recruiting

  • Om Research LLC ( Site 5045)

    Oxnard, California · Recruiting

  • Clinical Applications Laboratories ( Site 5123)

    San Diego, California · Recruiting

  • Amicis Research Center ( Site 5055)

    Valencia, California · Completed

  • University of Colorado Anschutz Medical Campus-Division of Gastroenterology and Hepatology ( Site 5026)

    Aurora, Colorado · Recruiting

  • Peak Gastroenterology Associates ( Site 5023)

    Colorado Springs, Colorado · Recruiting

  • South Denver Gastroenterology, PC ( Site 5132)

    Englewood, Colorado · Recruiting

  • Rocky Mountain Gastroenterology ( Site 5082)

    Lakewood, Colorado · Recruiting

  • Medical Research Center of Connecticut ( Site 5005)

    Hamden, Connecticut · Completed

  • Yale University School of Medicine-Digestive Disease ( Site 5019)

    New Haven, Connecticut · Recruiting

  • Emerson Clinical Research Institute ( Site 5051)

    Washington D.C., District of Columbia · Recruiting

  • Gastroenterology Consultants of Clearwater ( Site 5052)

    Clearwater, Florida · Active not recruiting

  • Covenant Metabolic Specialists, LLC ( Site 5150)

    Fort Myers, Florida · Recruiting

  • Nature Coast Clinical Research - Inverness ( Site 5042)

    Inverness, Florida · Recruiting

  • Atlantic Medical Research ( Site 5073)

    Margate, Florida · Active not recruiting

  • Sanchez Clinical Research ( Site 5144)

    Miami, Florida · Recruiting

  • AdventHealth Orlando ( Site 5131)

    Orlando, Florida · Recruiting

  • Endoscopic Research Inc ( Site 5061)

    Orlando, Florida · Recruiting

  • Orlando Health-Digestive Health Institute ( Site 5010)

    Orlando, Florida · Completed

  • USF Health Carol and Frank Morsani Center for Advanced Healthcare ( Site 5039)

    Tampa, Florida · Recruiting

  • Covenant Metabolic Specialists, LLC ( Site 5143)

    University Park, Florida · Recruiting

  • Morehouse School Of Medicine ( Site 5071)

    Atlanta, Georgia · Recruiting

  • Atlanta Center for Gastroenterology ( Site 5035)

    Decatur, Georgia · Completed

  • Gastroenterology Associates of Central Georgia ( Site 5048)

    Macon, Georgia · Recruiting

  • Eagle Clinical Research ( Site 5089)

    Chicago, Illinois · Completed

  • University of Chicago Medical Center ( Site 5066)

    Chicago, Illinois · Recruiting

  • Endeavor Health ( Site 5018)

    Evanston, Illinois · Recruiting

  • GI ALLIANCE - GURNEE ( Site 5003)

    Gurnee, Illinois · Recruiting

  • Indiana University Health University Hospital ( Site 5022)

    Indianapolis, Indiana · Recruiting

  • Iowa Digestive Disease Center ( Site 5007)

    Clive, Iowa · Recruiting

Showing 40 of 499 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.